Literature DB >> 16534559

Implantation of human demineralized bone matrix (DBM) for the treatment of juvenile bone cysts.

Hans-Jürgen Hass1, Hardy Krause, Steffen Kroker, Winfried Wagemann.   

Abstract

OBJECTIVE: Definitive bony consolidation in juvenile bone cysts. Prevention of pathologic fractures. Preservation of limb function. INDICATIONS: Juvenile bone cysts at all sites. CONTRAINDICATIONS: Malignant cystic lesions. SURGICAL TECHNIQUE: After opening and curettage, the cyst is packed with human demineralized bone matrix (DBM). POSTOPERATIVE MANAGEMENT: Clinical and radiologic checks after 1, 4, and 6 months, followed by further 6-monthly checks.
RESULTS: Over a period of 2 years, nine cysts packed with DBM showed almost totally osteodense images after an average of 8 months, with no other significant changes (follow-up period: 24 months). A typical decrease in cyst transparency on the plain radiographs was already detectable in all patients after 3-4 months. Marked cortical remodeling was visible after 6 months. A significant complication in one cyst in the distal tibial region was a pathologic fracture following distortion trauma; this occurred after 5 months, probably because of insufficient filling of the cyst. The fractured limb was immobilized in a lower-leg cast and healed sufficiently for stable weight bearing after 12 weeks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534559     DOI: 10.1007/s00064-006-1160-8

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  2 in total

Review 1.  Use of demineralized bone matrix in the extremities.

Authors:  Georgios I Drosos; Panagiotis Touzopoulos; Athanasios Ververidis; Konstantinos Tilkeridis; Konstantinos Kazakos
Journal:  World J Orthop       Date:  2015-03-18

2.  The available evidence on demineralised bone matrix in trauma and orthopaedic surgery: A systematic review.

Authors:  J van der Stok; K A Hartholt; D A L Schoenmakers; J J C Arts
Journal:  Bone Joint Res       Date:  2017-07       Impact factor: 5.853

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.